The objective of this study is to report on the bactericidal effects of blue light administered at low irradiance for extended periods of time. Multidrug-resistant organisms (MDROs) utilize biofilms that can limit the efficacy of antibiotics, causing infection and impaired wound healing. Unlike high-energy systems, continuous low-irradiance phototherapy (CLIP) avoids thermal injury of healthy tissue and can be delivered for extended periods. Four MDRO species, two of which contained different antibiotic resistance genes, were exposed to 405 nm irradiation . The microbes were incrementally exposed to increasing dose-rates (irradiance; mW/cm) over a 24-h time period. Cell viability and biomass reduction assays were conducted to quantify the antibacterial/antibiofilm effects. Primary human dermal fibroblasts were also exposed to CLIP to assess whether these dose-rates would impair cell viability or proliferation. CLIP exposure utilizing irradiances as low as 2.78 mW/cm delivered over 24 h resulted in a >3.0-log (>99.9%) and >2.0-log (>99.0%) microbial load reduction when organisms were grown in planktonic and biofilm-encapsulated conditions, respectively. Crystal violet biofilm assays revealed destruction of extracellular biofilm architecture following CLIP exposure. Human fibroblast viability and proliferation were unaffected by CLIP. This is the first report demonstrating the antimicrobial efficacy of CLIP for MDROs found in infected wounds. CLIP did not compromise cultured human fibroblast growth and survival. This study demonstrated that very low fluence rates (irradiances) delivered over extended periods are potently antimicrobial. There is translational potential for CLIP to be fabricated as a wearable device that would enable continuous ambulatory care of wounds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/photob.2022.0016 | DOI Listing |
Ann Neurol
January 2025
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.
Objective: Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is, in most cases, an early stage of Parkinson's disease or related disorders. Diagnosis requires an overnight video-polysomnogram (vPSG), however, even for sleep experts, interpreting vPSG data is challenging. Using a 3D camera, automated analysis of movements has yielded high accuracy.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital, Mölndal, Sweden.
Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).
Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.
Background: A generative model of tau PET was applied to multiple cohorts across the Alzheimer's disease (AD) spectrum, revealing longitudinal changes in tau production and transport. A generalisation of the model accounts for amyloid, tau and neurodegeneration (ATN) interactions and accurately explains longitudinal ATN biomarker data, adding potential for region specific and individualized tracking of ATN biomarkers.
Method: A model of tau spreading and production as measured through PET was developed and applied to longitudinal data from amyloid negative (A-), amyloid positive tau negative (A+T-) and amyloid positive tau positive (A+T+) cohorts from the Alzheimer's disease neuroimaging iniative (ADNI; N = 159) and BioFINDER-2 (BF2; N = 135) datasets.
Alzheimers Dement
December 2024
Institute for Neurodegenerative Diseases (IND) Florida, Boca Raton, FL, USA.
Background: Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), and other neurodegenerative diseases (NDD) develop over an extended preclinical period, sharing common risk factors and underlying pathophysiological mechanisms. Plasma proteins, including Amyloid-beta peptides (Aβ) and Tau isoforms, facilitate differential diagnosis of NDD in their earliest stages, allowing for timely delivery of targeted interventions. Blood-based biomarkers may also serve as a reliable means of monitoring disease progression and evaluating the effectiveness of individualized interventions across the spectrum of disease.
View Article and Find Full Text PDFBackground: Individuals with Mild Cognitive Impairment (MCI) are at greater risk of developing Alzheimer's disease (AD). Previous studies have shown that physical exercise is a protective factor against the clinical evolution of dementia in MCI. Lower muscle strength levels are associated with a greater risk of AD incidence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!